Compositions and methods for intrauterine insemination (iui)
AssigneeFerring B.V.
InventorsFrancois BISSONNETTE, Isaac-Jacques KADOCH
Life of this patent
Estimating the term…
Abstract
Methods, uses and compositions including FSH for use in the treatment of infertility by intrauterine insemination are described.
Claims21
1-22. (canceled)
A method of treating infertility by intrauterine insemination, comprising administering to a patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH), wherein the patient has a serum Anti-Mullerian hormone (AMH) level of <15 pmol/L, and wherein the composition is administered at a dose of, or equivalent to, from 0.048 μg to 0.052 μg, rFSH per kg bodyweight of the patient per day.
A method of treating infertility by intrauterine insemination, comprising administering to a patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH), wherein the patient has a serum Anti-Mullerian hormone (AMH) level of ≥15 pmol/L, and wherein the composition is administered at a dose of, or equivalent to, from 0.025 μg to 0.0475 μg rFSH per kg bodyweight of the patient per day.
A method of treating infertility by intrauterine insemination in a patient with PCOS, comprising administering to a PCOS patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH), wherein the PCOS patient has a serum Anti-Mullerian hormone (AMH) level of ≥23 pmol/L, and wherein the composition is administered at a dose of, or equivalent to, from 0.025 μg to 0.0475 μg rFSH per kg bodyweight of the patient per day.
A method of treating infertility by intrauterine insemination in a patient with PCOS, comprising administering to a PCOS patient in need thereof a composition comprising recombinant follicle stimulating hormone (rFSH) that includes α2,3- and α2,6 sialylation, wherein the composition is administered at a daily dose of 3 to 7 μg rFSH.
Dependencies are inferred from the claim text.